Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted
Thesis Summary

Nordson entered the final quarter of fiscal 2026 with record quarterly sales, broad-based organic growth, a 35% larger backlog, a 32% EBITDA margin and raised full-year guidance. Advanced Technology Solutions was the principal growth engine, while Medical and Fluid Solutions also produced double-digit organic growth excluding the divested contract-manufacturing business. The 15% dividend increase and 63-year record of annual increases reinforce the quality and cash-generation case.

Sign in / Sign up to read more
This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.
Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026
Low · most bearish analyst$260.00
Mean target$316.86
High · most bullish analyst$345.00
Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026
Scenarios · 12-month scenario targetsAnchored at research date
Bear CaseDownside scenario
$260.0020%

Backlog conversion weakens, electronics demand reverses, or macroeconomic, tariff and currency pressures interrupt the current organic-growth momentum. A result below the lower end of either full-year guidance range would undermine the operating assumptions supporting the base case.

Base CaseCentral scenario
$316.8655%
Matches the consensus mean

Order and backlog momentum supports fiscal 2026 sales within the stated $3.035-$3.075 billion range and adjusted diluted EPS within the stated $11.80-$12.00 range, with Advanced Technology Solutions remaining the fastest-growing segment.

Bull CaseUpside scenario
$345.0025%

Backlog converts on schedule, electronics dispense and test-and-inspection demand remains strong, and growth stays broad across all three segments. This would create a path to finish above the upper ends of the current fiscal 2026 sales and adjusted-EPS ranges.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits
  • Fiscal Q3 2026 sales reached a quarterly record of $817.7 million, with total organic growth of 11.7% and growth reported across all three segments.
  • Backlog increased 35% year over year, providing near-term demand visibility entering fiscal Q4 2026.
  • Quarterly EBITDA reached a record $262.5 million, or 32% of sales, while year-to-date free-cash-flow conversion was 125%.
  • The board raised the quarterly dividend 15% to $0.94 per share, extending Nordson's annual dividend-increase record to 63 consecutive years.
Sign in / Sign up to read more
Key Investment Risks
  • Advanced Technology Solutions generated 30.9% organic growth in fiscal Q3 2026, making continued electronics strength an important component of the current momentum.
  • Acquisitions and divestitures can affect comparability and execution; the Medical and Fluid Solutions growth presentation excluded the prior-year contract-manufacturing divestiture.
  • Management identifies economic and political conditions, tariffs, currency movements, acquisition integration and geopolitical events as uncertainties affecting forward-looking expectations.
Sign in / Sign up to read more

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Explore this dossier

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.